No Detail Found!

Effect of three different doses of intrathecal dexmedetomidine on subarachnoid block: a prospective randomized double-blind trial

Author(s)
Ashita Mowar Shri Ram Murti SmarakInstitute of Medical Sciences,Bareilly - Nainital Rd, Rama Murti Nagar, Bhoji Pura, Uttar Pradesh ,India
Vishwadeep Singh Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly - Nainital Rd, Rama Murti Nagar, Bhoji Pura, Uttar Pradesh , India
Geeta Karki Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly - Nainital Rd, Rama Murti Nagar, Bhoji Pura, Uttar Pradesh , India
Akhilesh Pahade Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly - Nainital Rd, Rama Murti Nagar, Bhoji Pura, Uttar Pradesh 243202, India
Abstract
Background: Dexmedetomidine has increasingly been used in regional anesthesia as an adjuvant, but there is still no consensus on the optimum dose when it is used intrathecally. We conducted this study to elucidate the doseresponse relation between three different doses of intrathecal dexmedetomidine (2.5, 5, or 10 µg) as an adjuvant to 0.5% hyperbaric bupivacaine in patients undergoing elective lower abdominal and lower limb surgeries. Methodology: 90 patients, aged 18-60 y, were randomized into three groups of 30 patients each. Group A received 0.5% hyperbaric bupivacaine 12.5 mg (2.5 ml) with 2.5 µg dexmedetomidine, Group B received 5 µg dexmedetomidine with bupivacaine, and Group C received 10 µg dexmedetomidine with bupivacaine. Duration of the spinal sensory blockade (primary outcome), onset of the blockade, time to rescue analgesia, level of sedation, duration of motor blockade, comparison of hemodynamic variables and complications, if any were assessed. Results: There was a significant dose dependent prolongation of sensory block; Group A - 250.67 ± 51.39, Group B 286 ± 52.76, and Group C - 351.00 ± 47.00 min; (p < 0.001), motor block; Group A - 255.53 ± 44.25, Group B - 312 ± 29.64, and Group C - 361.4 ± 16.14 min (p < 0.001). Time to two segment regression was 132.33 ± 48.29, 148.77 ± 48.89, 171.57 ± 25.46 min (p = 0.002) and time for rescue analgesia was 351.33 ± 101.19, 472.00 ± 24.41, 738.00 ± 67.79 min (p < 0.001). VAS was significantly low in Group C (p < 0.05). Intergroup hemodynamic parameters were comparable (p > 0.05) without any appreciable side effects. Conclusion: Spinal dexmedetomidine increases the sensory and motor block durations as well as time to first analgesic use, and decreases analgesic consumption in a dose-dependent manner, when used with hyperbaric bupivacaine. 
Publication Details
Page(s) 8-13
Published Journal: Anaesthesia, Pain and Intensive Care, Volume: 26, Issue: 1, Year: 2022

Request the full text from PASTIC

Keywords
Dexmedetomidine, Dexmedetomidine, Spinal, Anesthesia, Bupivacaine, Post-operative analgesia
0

Citations

0

Downloads

46

Views